Furthermore, targetable mutations, possibly driving tumor progression and/or treatment resistance, can be found in subpopulations of aggressive tumors, e.g., ALK mutations in neuroblastoma (Schleiermacher et al. 2014). The gene discussed is ALK; the disease is neoplasm.